Zoom memorials highlight the ironic cruelty of trying to mourn together during the pandemic
Canva

Earlier this month, I attended my first Zoom wedding. A week after that, I attended a Zoom baby shower.

Tomorrow, I'll attend a Zoom gathering to mourn the loss of a family friend. His name was Peter. He died of COVID-19 last week.

This gathering isn't technically a funeral or memorial service, but rather a virtual devotional taking place on Zoom at the same time as Peter's physical burial. A few close friends and family will gather at the gravesite—masked and distanced—while the rest of us share readings and prayers over Zoom to honor his interment.

It's weird. There's no other way to say it. With the wedding and baby shower, we all sort of laughed our way through the weirdness. We acknowledged the bummer of not being able to get together, but at this point we're all accustomed to having to meet virtually. Zoom celebrations are better than no celebrations at all.

But mourning this way feels...different. We can't laugh away the awkwardness of it when the Zoom meeting itself is a reminder of the tragic cause of our friend's death.


Celebratory gatherings are fun, but not necessary. Gathering when someone dies feels necessary in a way, and the inability to do that adds an extra layer of loss to the grief we're already experiencing. Normally, our whole community would gather together to honor Peter's life tomorrow. We'd put on appropriate funeral attire, stand side by side at his grave, hold hands or hug one another as we mark the momentousness of his passing. We'd all bring food and break bread together as we share stories of his life. We'd pass around tissues, crying and laughing and sharing in the oh-so-human experience of bringing together the lives he had touched.

But we can't do any of that. If we did, we'd run the risk of having to do it all over again for another friend or loved one taken too soon by this stupid virus. So we do what we can do and deal with the strange questions—What does one wear to a Zoom mourning? How long it will be before we can actually gather for a real memorial service? Will it feel like it's too late then? Will we want to do that in the midst of celebrating a return to non-distanced life?

This pandemic has taken so much, and each thing stings in its own way. The death toll itself is overwhelming, especially here in the U.S. where we have already lost more than 330,000 lives. A hundred 9/11s and counting. Five Vietnams in less than a year. It's unreal. In the beginning, we were told that all of us would likely end up knowing someone who died of COVID-19, and some people have now lost multiple family members. More will follow as we head into the deadliest month of the pandemic. That's not doom and gloom forecasting—that's the reality of the current moment.

But the loss of in-person mourning as millions are losing loved ones before they expected to is a tragedy in and of itself. There's a cruel irony in it, that we can't gather in person to mourn if we want to stop the thing that's making it so we can't gather in person to mourn. When we need the comfort of coming together the most, we can't, as indulging in that comfort could lead to even more suffering. Of all of the sacrifices we've had to make, the loss of communal mourning is one of the hardest.

And so we open our computers and enter our virtual meeting rooms and try to comfort one another through our grief amid the inevitable unmute reminders. It's weird. It all feels wrong. But it's necessary. We need to mourn our losses together. We also need to be able to mourn the fact that we're not able to do that the way we want to.

There is gratitude to be found in all of this, of course. It's pretty incredible that we live in a time when we have the technology to at least see one another's faces and hear people's voices as we share our losses at a distance. If this pandemic had hit in my childhood, we'd have had no community ability to mourn at all. A Zoom gathering to mourn is better than no gathering at all—but it's still all of the weird, wrong, sad things at once.

And what's extra painful about it is that it didn't have to be this way. Next time we have a pandemic, let's all agree to just follow New Zealand's lead, shall we? Hundreds of thousands of Zoom funerals really ought to be enough to get us all on the same page.

Photo by NeONBRAND on Unsplash

I'll never forget the exhilaration I felt as I headed into the city on July 3, 2018. My pink hair was styled. I wore it up in a high ponytail, though I left two tendrils down. Two tendrils which framed my face. My makeup was done. I wore shadow on my eyes and blush on my cheeks, blush which gave me color. Which brought my pale complexion to life. And my confidence grew each time my heels clacked against the concrete.

My confidence grew with each and every step.

Why? Because I was a strong woman. A city woman. A woman headed to interview for her dream job.

I nailed the interview. Before I boarded the bus back home, I had an offer letter in my inbox. I was a news writer, with a salary and benefits, but a strange thing happened 13 months later. I quit said job in an instant. On a whim. I walked down Fifth Avenue and never looked back. And while there were a few reasons why I quit that warm, summer day: I was a new(ish) mom. A second-time mom, and I missed my children. Spending an hour with them each day just wasn't enough. My daughter was struggling in school. She needed oversight. Guidance. She needed my help. And my commute was rough. I couldn't cover the exorbitant cost of childcare. The real reason I quit was because my mental health was failing.


Keep Reading Show less
Photo by NeONBRAND on Unsplash

I'll never forget the exhilaration I felt as I headed into the city on July 3, 2018. My pink hair was styled. I wore it up in a high ponytail, though I left two tendrils down. Two tendrils which framed my face. My makeup was done. I wore shadow on my eyes and blush on my cheeks, blush which gave me color. Which brought my pale complexion to life. And my confidence grew each time my heels clacked against the concrete.

My confidence grew with each and every step.

Why? Because I was a strong woman. A city woman. A woman headed to interview for her dream job.

I nailed the interview. Before I boarded the bus back home, I had an offer letter in my inbox. I was a news writer, with a salary and benefits, but a strange thing happened 13 months later. I quit said job in an instant. On a whim. I walked down Fifth Avenue and never looked back. And while there were a few reasons why I quit that warm, summer day: I was a new(ish) mom. A second-time mom, and I missed my children. Spending an hour with them each day just wasn't enough. My daughter was struggling in school. She needed oversight. Guidance. She needed my help. And my commute was rough. I couldn't cover the exorbitant cost of childcare. The real reason I quit was because my mental health was failing.


Keep Reading Show less
True

Each year, an estimated 1.8 million people in the United States are affected by cancer — most commonly cancers of the breast, lung, prostate, and blood cancers such as leukemia. While not everyone overcomes the disease, thanks to science, more people are surviving — and for longer — than ever before in history.

We asked three people whose lives have been impacted by cancer to share their stories – how their lives were changed by the disease, and how they're using that experience to change the future of cancer treatments with the hope that ultimately, in the fight against cancer, science will win. Here's what they had to say.

Celine Ryan, 55, engineer database programmer and mother of five from Detroit, MI

Photo courtesy of Celine Ryan

In September 2013, Celine Ryan woke up from a colonoscopy to some traumatic news. Her gastroenterologist showed her a picture of the cancerous mass they found during the procedure.

Ryan and her husband, Patrick, had scheduled a colonoscopy after discovering some unusual bleeding, so the suspicion she could have cancer was already there. Neither of them, however, were quite prepared for the results to be positive -- or for the treatment to begin so soon. Just two days after learning the news, Ryan had surgery to remove the tumor, part of her bladder, and 17 cancerous lymph nodes. Chemotherapy and radiation soon followed.

Ryan's treatment was rigorous – but in December 2014, she got the devastating news that the cancer, once confined to her colon, had spread to her lungs. Her prognosis, they said, was likely terminal.

But rather than give up hope, Ryan sought support from online research, fellow cancer patients and survivors, and her medical team. When she brought up immunotherapy to her oncologist, he quickly agreed it was the best course of action. Ryan's cancer, like a majority of colon and pancreatic cancers, had been caused by a defect on the gene KRAS, which can result in a very aggressive cancer that is virtually "undruggable." According to the medical literature, the relatively smooth protein structure of the KRAS gene meant that designing inhibitors to bind to surface grooves and treat the cancer has been historically difficult. Through her support systems, Ryan discovered an experimental immunotherapy trial at the National Institutes of Health (NIH) in Bethesda, MD., and called them immediately to see if she was eligible. After months of trying to determine whether she was a suitable candidate for the experimental treatment, Ryan was finally accepted.

The treatment, known as tumor-infiltrating lymphocyte therapy, or TIL, is a testament to how far modern science has evolved. With this therapy, doctors remove a tumor and harvest special immune cells that are found naturally in the tumor. Doctors then grow the cells in a lab over the next several weeks with a protein that promotes rapid TIL growth – and once the cells number into the billions, they are infused back into the patient's body to fight the cancer. On April 1, 2015, Ryan had her tumor removed at the NIH. Two months later, she went inpatient for four weeks to have the team "wash out" her immune system with chemotherapy and infuse the cells – all 148 billion of them – back into her body.

Six weeks after the infusion, Ryan and Patrick went back for a follow-up appointment – and the news they got was stunning: Not only had no new tumors developed, but the six existing tumors in her lungs had shrunk significantly. Less than a year after her cell infusion, in April 2016, the doctors told Ryan news that would have been impossible just a decade earlier: Thanks to the cell infusion, Ryan was now considered NED – no evaluable disease. Her body was cancer-free.

Ryan is still NED today and continuing annual follow-up appointments at the NIH, experiencing things she never dreamed she'd be able to live to see, such as her children's high school and college graduations. She's also donating her blood and cells to the NIH to help them research other potential cancer treatments. "It was an honor to do so," Ryan said of her experience. "I'm just thrilled, and I hope my experience can help a lot more people."

Patrice Lee, PhD, VP of Pharmacology, Toxicology and Exploratory Development at Pfizer

Photo courtesy of Patrice Lee

Patrice Lee got into scientific research in an unconventional way – through the late ocean explorer Jacques Cousteau.

Lee never met Cousteau but her dreams of working with him one day led her to pursue a career in science. Initially, Lee completed an undergraduate degree in marine biology; eventually, her interests changed and she decided to get a dual doctoral degree in physiology and toxicology at Duke University. She now works at Pfizer's R&D site in Boulder, CO (formerly Array BioPharma), leading a group of scientists who determine the safety and efficacy of new oncology drugs.

"Scientists focused on drug discovery and development in the pharmaceutical industry are deeply committed to inventing new therapies to meet unmet needs," Lee says, describing her field of work. "We're driven to achieve new medicines and vaccines as quickly as possible without sacrificing safety."

Among the drugs Lee has helped develop during her career, including cancer therapies, she says around a dozen are currently in development, while nine have received FDA approval — an incredible accomplishment as many scientists spend their careers without seeing their drug make it to market. Lee's team is particularly interested in therapies for brain metastases — something that Lee says is a largely unmet need in cancer research, and something her team is working on from a variety of angles. "Now that we've had rapid success with mRNA vaccine technology, we hope to explore what the future holds when applying this technology to cancers," Lee says.

But while evaluating potential cancer therapies is a professional passion of Lee's, it's also a mission that's deeply personal. "I'm also a breast cancer survivor," she says. "So I've been on the other side of things and have participated in a clinical trial."

However, seeing how melanoma therapies that she helped develop have affected other real-life cancer patients, she says, has been a highlight of her career. "We had one therapy that was approved for patients with BRAF-mutant metastatic melanoma," Lee recalls. "Our team in Boulder was graced by a visit from a patient that had benefited from these drugs that we developed. It was a very special moment for the entire team."

None of these therapies would be available, Lee says without rigorous science behind it: "Facts come from good science. Facts will drive the development of new drugs, and that's what will help patients."

Chiuying "Cynthia" Kuk (they/them) MS, 34, third-year medical student at Michigan State University College of Human Medicine

Photo courtesy of Cynthia Kuk

Cynthia Kuk was just 10 years old when they had a conversation that would change their life forever.

"My mother, who worked as a translator for the government at the time, had been diagnosed with breast cancer, and after her chemotherapy treatments she would get really sick," Kuk, who uses they/them pronouns, recalls. "When I asked my dad why mom was puking so much, he said it was because of the medicine she was taking that would help her get better."

Kuk's response was immediate: "That's so stupid! Why would a medicine make you feel worse instead of better? When I'm older, I want to create medicine that won't make people sick like that."

Nine years later, Kuk traveled from their native Hong Kong to the United States to do exactly that. Kuk enrolled in a small, liberal arts college for their Bachelor's degree, and then four years later started a PhD program in cancer research. Although Kuk's mother was in remission from her cancer at the time, Kuk's goal was the same as it had been as a 10-year-old watching her suffer through chemotherapy: to design a better cancer treatment, and change the landscape of cancer research forever.

Since then, Kuk's mission has changed slightly.

"My mom's cancer relapsed in 2008, and she ended up passing away about five years after that," Kuk says. "After my mom died, I started having this sense of urgency. Cancer research is such that you work for twenty years, and at the end of it you might have a fancy medication that could help people, but I wanted to help people now." With their mother still at the forefront of their mind, Kuk decided to quit their PhD program and enter medical school.

Now, Kuk plans to pursue a career in emergency medicine – not only because they are drawn to the excitement of the emergency room, but because the ER is a place where the most marginalized people tend to seek care.

"I have a special interest in the LGBTQ+ population, as I identify as queer and nonbinary," says Kuk. "A lot of people in this community and other marginalized communities access care through the ER and also tend to avoid medical care since there is a history of mistreatment and judgement from healthcare workers. How you carry yourself as a doctor, your compassion, that can make a huge difference in someone's care."

In addition to making a difference in the lives of LGBTQ+ patients, Kuk wants to make a difference in the lives of patients with cancer as well, like their mother had.

"We've diagnosed patients in the Emergency Department with cancer before," Kuk says. "I can't make cancer good news but how you deliver bad news and the compassion you show could make a world of difference to that patient and their family."

During their training, Kuk advocates for patients by delivering compassionate and inclusive care, whether they happen to have cancer or not. In addition to emphasizing their patient's pronouns and chosen names, they ask for inclusive social and sexual histories as well as using gender neutral language. In doing this, they hope to make medicine as a whole more accessible for people who have been historically pushed aside.

"I'm just one person, and I can't force everyone to respect you, if you're marginalized," Kuk says. "But I do want to push for a culture where people appreciate others who are different from them."